Merck & Co Inc. is seeking to raise as much as $8 billion through a corporate bond sale, with part of the proceeds expected ...

Merck (MRK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Halozyme is seeing some progress in its global effort to defend intellectual property against alleged infringement by Merck & ...

Merck & Co., Inc. (NYSE:MRK) is one of the Cheap NYSE Stocks to Buy Now. On December 5, an analyst from Guggenheim raised the ...

Patients with polycythemia vera (PV), a rare cancer characterized by overabundant red blood cells, have endured years of middling progress in their therapeutic options. | Patients with polycythemia ...

After a drawn-out litigation process, Merck & Co. seems to have finally washed its hands of more than a thousand lawsuits tied to its shingles vaccine Zostavax. Late last week, the U.S. Court of ...

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the company inked with Austria-based drug delivery technology maker Cyprumed.

Merck & Co has a lower P/E than the aggregate P/E of 57.45 of the Pharmaceuticals industry. Ideally, one might believe that ...

Merck & Co., Inc. (MRK) is a leading global healthcare company specializing in the research, development, and distribution of prescription medicines, vaccines, and animal health products. Its ...

Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer discussed, along with the tech battleground. Cramer highlighted ...

Merck's shares have declined, making its dividend yield climb and valuation compress, presenting an attractive investment opportunity at current prices. Keytruda, the company's largest drug, continues ...

A top U.S. health official's call to split the measles-mumps-rubella (MMR) vaccine into separate shots sparked strong pushback from Merck & Co., Inc. (NYSE:MRK) and medical experts, who said such a ...